

Planned filings 2014 to ≥ 2018

2014	2015	2016	2017	≥ 2018	
LBH589 * Multiple Myeloma	BKM120 mBC ER+ AI resistant/mTOR naive	BYM338 sIBM ¹⁰	DEB025 HCV infection	AUY922 Solid tumors	QAW039 Asthma
LCQ908 FCS ¹	MEK162 NRAS Mutant Melanoma	CTL019 Leukemia	KAE609 Malaria	BAF312 Multiple sclerosis	QAX576 Allergic diseases
LCZ696 Heart failure (REF) ²	PKC412 AML ⁵	Fovista® Wet AMD	LCI699 Cushing's Disease	BCT197 COPD ¹⁸	QGE031 Allergic diseases
LDE225 ** Advanced Basal Cell Carcinoma	Afinitor® Non-functioning GI and Lung NET ⁶	LEE011 Breast cancer	TKI258 Solid tumors	BGJ398 Solid tumors	BKM120 Solid tumors
Zykadia™ *** ALK+ advanced NSCLC ³	Afinitor® TSC ⁷ Seizure	LGX818 BRAF Mutant Melanoma	ACZ885 Sec. Prev. CV events ¹⁶	BGS649 OHH ¹⁹	BYM338 Hip fracture
Afinitor® HER2+ Breast cancer 1 st Line	AIN457 Ankylosing spondylitis	MEK162 + LGX818 BRAF Mutant Melanoma	Afinitor® DLBCL ¹⁷	BYL719 Solid tumors	LCZ696 Heart failure (PEF) ²⁰
Afinitor® HER2+ Breast cancer 2 nd /3 rd Line	AIN457 Rheumatoid arthritis	RLX030 Acute Heart Failure	Seebri® Asthma	CAD106 Alzheimer's disease	LDE225 Medulloblastoma
AIN457 Psoriatic arthritis	Gilena™ PPMS ⁸	BKM120 mBC ER+ post AI and mTOR inhibitor		EDP239 HCV infection	LDE225 Solid tumors
Jakavi® **** Polycythemia vera	PKC412 ASM ⁹	Gilena™ CIDP ¹¹		FCR001 Renal transplantation	LEE011 Solid tumors
Exjade® FCT ⁴ ***** Iron overload		Ilaris® Hereditary Periodic Fevers		HSC835 Stem cell transplantation	LGX818 Solid tumors
		Lucentis® CNV and ME ¹²		LIK066 Type II diabetes	Lucentis® ROP ²¹
		MEK162 LGSOC ¹³		LJM716 Solid tumors	MEK162 Solid tumors
		Tasigna® CML Treatment free remission			
		Tekturna® Heart failure ¹⁴			
		Zykadia™ ALK+advanced NSCLC ³ (first line, treatment naive)			
		Signifor® LAR ¹⁵ Cushing's Disease			

* LBH589 was filed in the US and EU in Q2 2014

** LDE225 was filed in EU in Q2 2014

*** Zykadia™ (ceritinib) was approved in the US on April 29, 2014

**** Jakavi® was filed in the EU in Q2 2014

***** Exjade® FCT was submitted in the US in Q2 2014

New molecule
New indication
New formulation

¹ Familial chylomicronemia syndrome

² Reduced ejection fraction

³ Non-small cell lung cancer

⁴ Film-coated table

⁵ Acute myeloid leukemia

⁶ Neuroendocrine tumors

⁷ Tuberous sclerosis complex

⁸ Primary progressive multiple sclerosis

⁹ Aggressive systemic mastocytosis

¹⁰ Sporadic inclusion body myositis

¹¹ Chronic inflammatory demyelinating polyradiculoneuropathy

¹² Choroidal neovascularization (CNV) and macular edema (ME) secondary to conditions other than macular degeneration, diabetic macular edema, retinal vein occlusion and pathologic myopia

¹³ Low-grade serous ovarian cancer

¹⁴ Reduction of CV death/hospitalization in chronic heart failure patients

¹⁵ Long-acting release

¹⁶ Secondary prevention of cardiovascular events

¹⁷ Diffuse large B-cell lymphoma

¹⁸ Chronic obstructive pulmonary disease

¹⁹ Obese hypogonadotropic hypogonadism

²⁰ Preserved ejection fraction

²¹ Retinopathy of prematurity